Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

June 23, 2009

Date of Report

(Date of earliest event reported)

 

 

ZYMOGENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Washington   000-33489   91-1144498

(State or Other Jurisdiction

of Incorporation)

   (Commission File No.)  

(IRS Employer

Identification No.)

1201 Eastlake Avenue East, Seattle, Washington 98102-3702

(Address of Principal Executive Offices, including Zip Code)

(206) 442-6600

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 7.01. Regulation FD Disclosure.

On June 23, 2009, ZymoGenetics, Inc. (the “Company”) earned a milestone payment in the amount of $25 million from Bristol-Myers Squibb Company (“BMS”) related to the parties’ progress toward Phase 2 testing under the previously announced global collaboration with BMS for PEG-Interferon lambda. ZymoGenetics expects to receive the payment within 30 days after the milestone event. This brings the total milestone payments received or receivable from BMS in 2009 to date to $130 million. An additional $70 million milestone payment will be due within 30 days after initiation of Phase 2 patient treatment.

Information in this Report on Form 8-K (the “Report”) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing. This Report will not be deemed an admission as to the materiality of any information in the Report that is being disclosed pursuant to Regulation FD.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ZYMOGENETICS, INC.
Dated: June 25, 2009   By  

/s/    James A. Johnson

    James A. Johnson
    Executive Vice President and
    Chief Financial Officer